Kulkarni, Tejaswini http://orcid.org/0000-0002-4251-4988
Newton, Chad A. http://orcid.org/0000-0001-5256-9029
Gupta, Sachin http://orcid.org/0000-0003-2912-5619
Samara, Katerina http://orcid.org/0000-0001-5710-1943
Bernstein, Elana J. http://orcid.org/0000-0001-5560-6390
Clinical trials referenced in this document:
Documents that mention this clinical trial
M32 Effect of pirfenidone on all-cause mortality (acm) and forced vital capacity (fvc) in idiopathic pulmonary fibrosis (ipf) patients with low fvc and/or low dlco: analysis of pooled data from ascend and capacity
https://doi.org/10.1136/thoraxjnl-2017-210983.454
Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies
https://doi.org/10.1007/s12325-023-02565-3
M27 Effect of pirfenidone on breathlessness as measured by the ucsd-sobq score in patients with idiopathic pulmonary fibrosis (ipf) with moderate lung function impairment
https://doi.org/10.1136/thoraxjnl-2017-210983.449
Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis
https://doi.org/10.1136/thoraxjnl-2021-218577
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
https://doi.org/10.1136/bmjresp-2015-000105
The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial
https://doi.org/10.1007/s41030-024-00267-x
Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
https://doi.org/10.1136/bmjresp-2018-000331
Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials
https://doi.org/10.1136/bmjresp-2018-000323
Funding for this research was provided by:
F. Hoffmann-La Roche
Article History
Received: 22 February 2024
Accepted: 25 June 2024
First Online: 29 July 2024
Declarations
:
: Tejaswini Kulkarni reports consultancy and speaker fees from Boehringer Ingelheim and consultancy fees from Aileron Therapeutics, PureTech LYT-100 Inc., United Therapeutics Corporation and Veracyte. Chad A. Newton reports consultancy fees from Boehringer Ingelheim. Dr. Newton is supported by the National Heart, Lung, and Blood Institute (K23 HL148498). Sachin Gupta is an employee of Genentech, Inc. Katerina Samara is an employee of F. Hoffmann-La Roche, Ltd. Elana J. Bernstein reports grants, consultancy fees and support for meeting attendance from Boehringer Ingelheim. Dr. Bernstein is also supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number K23 AR075112), the National Heart, Lung, and Blood Institute (grant number R01 HL164758), and the Department of Defence (grant number W81XWH2210163).
: The ASCEND trial was conducted in compliance with Good Clinical Practice as described in FDA regulations and the 1996 International Council for Harmonisation document, in consistence with the principles stated in the Declaration of Helsinki. The protocol for the ASCEND trial was approved by the institutional review board or ethics committee at each participating centre and all patients provided written informed consent for participation in the trial. No prospective data were collected during this post-hoc analysis; therefore, ethical approval was not required.